Levitee Labs announces partnership with Adracare to provide psychedelic digital care for addiction and mental health treatment

18 October, 2021

Levitee Labs announces partnership with Adracare to provide psychedelic digital care for addiction and mental health treatment

The Vancouver-based company is integrating psychedelic medicine services into traditional healthcare infrastructure

Levitee Labs -
The Adracare platform will unify several core functionalities under a single platform for Levitee Labs

Levitee Labs (CSE:LVT) Inc said it has partnered with Adracare Inc, a subsidiary of WELL Health Technologies Corp, for support in value-based digital care to patients suffering from addiction and mental health issues.

The Vancouver-based company is integrating psychedelic medicine services into traditional healthcare infrastructure. Adracare’s technology services, including videoconferencing, would make mental health services more accessible for patients while bringing down the delivery cost for healthcare professionals.

READ: Levitee Labs announces appointment of Dr Mohammed H. Mosli, as chief people officer of Levitee Clinics and Levitee Pharmacies

 

The Adracare platform will unify several core functionalities under a single platform for Levitee Labs (CSE:LVT), providing a unique entry point for patients in receiving affordable digital care and easier follow-ups during their recovery process, the release said.

“We believe Adracare is a world-class partner with which to build out a telemedicine and integrated technology platform, with the goal of delivering psychedelic-inspired medicines and experimental therapies combined with digital therapeutics,” said Pouya Farmand, CEO of Levitee Labs.

The collaborative model will integrate ethical considerations of digital technologies into a platform that includes clinical workflows, evidence-based care, and shared decision-making. Levitee said that the partnership will also serve as an opportunity to scale psychedelic therapies to various communities across Canada, where there is a critical shortage of in-person care providers.

The integrative wellness company is currently operating five clinics and three pharmacies, primarily based in Alberta, which see approximately 35,000 patients a year.

“We are delighted to partner with Levitee Labs, to empower them with a leading digital platform to support their growth. Adracare provides a strong turnkey practice management platform with native telehealth and patient engagement capabilities to deliver a personalized experience for mental health providers and patients,” said Shervin Bakhtiari, general manager of digital health apps at WELL in a release.

In psychedelic-assisted therapy, set and setting play an important role for treatment to be effective. The at-home therapy option with Adracare will help patients in a comfortable setting, while alleviating any accessibility barriers. Other services like one-on-one counseling, group therapy, consultations, and psychedelic treatments will be made available through the partnership.

Appointments can be booked online, patient communications are sent via email and text messaging, and a virtual visit may occur, all within the same technology platform, Levitee shared.

Levitee Labs is establishing itself as a leader in the integrative wellness space. Through an M&A regimen that focuses on the centralization of complementary integrative wellness assets, the company is focused on transforming mental health and addiction treatments through the integration of psychedelic medicines and alternative therapies.

Contact Ritika at ritika@proactiveinvestors.com

Learn more: Levitee Labs Announces Agreement with Adracare, a WELL Health Company, to Support Individuals with Addiction and Mental Health Conditions

Would you like to know more?

Contact us